AFELETECAN HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C45H49N7O11S.ClH
Molecular Weight	932.437
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC[C@@]4(OC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=S)NC2=CC=C(O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)[C@@H]3O)C=C2)C(C)C)C(=O)OCC5=C4C=C6N(CC7=CC8=CC=CC=C8N=C67)C5=O

InChI

InChIKey=XQWYWSHYKUJQDC-NZGUGFNHSA-N

InChI=1S/C45H49N7O11S.ClH/c1-6-45(30-17-33-35-25(15-24-9-7-8-10-31(24)49-35)19-52(33)40(56)29(30)20-60-43(45)58)63-41(57)34(22(2)3)51-39(55)32(16-27-18-46-21-47-27)50-44(64)48-26-11-13-28(14-12-26)62-42-37(54)38(59-5)36(53)23(4)61-42;/h7-15,17-18,21-23,32,34,36-38,42,53-54H,6,16,19-20H2,1-5H3,(H,46,47)(H,51,55)(H2,48,50,64);1H/t23-,32-,34-,36+,37-,38+,42+,45-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C45H49N7O11S
Molecular Weight	895.976
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800013469 | https://www.ncbi.nlm.nih.gov/pubmed/16133797

Afeletecan (Bay 38-3441) is a camptothecin glycoconjugate which stabilizes the active lactone form of camptothecin and allows selective uptake into tumor cells. Afeletecan is a topoisomerase inhibitor. Afeletecan was in phase I clinical trials with Bayer for the treatment of cancer; however, development appears to have been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Gateways to clinical trials.	2003 Jul-Aug	12949633
Gateways to clinical trials. March 2003.	2003 Mar	12731460
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.	2005 Oct	16133797

Patents

Sample Use Guides

In Vivo Use Guide

Solid tumors: A total of 81 patients with advanced solid tumors were treated with BAY 38-3441 either at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule), or at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule). 3-day schedule for BAY 38-3441 at a dose of 320 mg/m2/day as 30-min infusions for further phase II studies was recommended.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:41:32 GMT 2023` Edited by `admin` on `Fri Dec 15 15:41:32 GMT 2023`
Record UNII	DTJ7VPW43J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AFELETECAN HYDROCHLORIDE

Common Name

English

BAY 56-3722

Code

English

BAY56-3722

Code

English

L-VALINE, N-(((4-((6-DEOXY-3-O-METHYL-.BETA.-L-GALACTOPYRANOSYL)OXY)PHENYL)AMINO)THIOXOMETHYL)-L-HISTIDYL-, (4S)-4-ETHYL-3,4,12,14-TETRAHYDRO-3,14-DIOXO-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-4-YL ESTER, HYDROCHLORIDE (1:1)

Common Name

English

L-VALINE, N-(((4-((6-DEOXY-3-O-METHYL-.BETA.-L-GALACTOPYRANOSYL)OXY)PHENYL)AMINO)THIOXOMETHYL)-L-HISTIDYL-, (4S)-4-ETHYL-3,4,12,14-TETRAHYDRO-3,14-DIOXO-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-4-YL ESTER, MONOHYDROCHLORIDE

Common Name

English

BAY-563722

Code

English

BAY 38-3441

Brand Name

English

Afeletecan hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2843